Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

Irinotecan 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Acinar Cell × Gemcitabine × Clear all
NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

Phase 1/2 Recruiting
442 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡